JP2023532904A - 修飾il-2ポリペプチドを含むポリペプチド及びその使用 - Google Patents

修飾il-2ポリペプチドを含むポリペプチド及びその使用 Download PDF

Info

Publication number
JP2023532904A
JP2023532904A JP2022580769A JP2022580769A JP2023532904A JP 2023532904 A JP2023532904 A JP 2023532904A JP 2022580769 A JP2022580769 A JP 2022580769A JP 2022580769 A JP2022580769 A JP 2022580769A JP 2023532904 A JP2023532904 A JP 2023532904A
Authority
JP
Japan
Prior art keywords
polypeptide
binding domain
antigen binding
modified
substitution
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2022580769A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023532904A5 (cg-RX-API-DMAC7.html
Inventor
ジョン シー. ティマー
フロリアン スルツマイアー
ケイトリン エム. ウィリス
ブライアン ベックランド
ブレンダン ピー. エッケルマン
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sanofi Aatd Inc
Original Assignee
Inhibrx Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Inhibrx Inc filed Critical Inhibrx Inc
Publication of JP2023532904A publication Critical patent/JP2023532904A/ja
Publication of JP2023532904A5 publication Critical patent/JP2023532904A5/ja
Priority to JP2026032254A priority Critical patent/JP2026094308A/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/55—IL-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/2013—IL-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Toxicology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Biomedical Technology (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Hematology (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
JP2022580769A 2020-07-02 2021-07-01 修飾il-2ポリペプチドを含むポリペプチド及びその使用 Pending JP2023532904A (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2026032254A JP2026094308A (ja) 2020-07-02 2026-03-02 修飾il-2ポリペプチドを含むポリペプチド及びその使用

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063047681P 2020-07-02 2020-07-02
US63/047,681 2020-07-02
PCT/US2021/040061 WO2022006380A2 (en) 2020-07-02 2021-07-01 Polypeptides comprising modified il-2 polypeptides and uses thereof

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2026032254A Division JP2026094308A (ja) 2020-07-02 2026-03-02 修飾il-2ポリペプチドを含むポリペプチド及びその使用

Publications (2)

Publication Number Publication Date
JP2023532904A true JP2023532904A (ja) 2023-08-01
JP2023532904A5 JP2023532904A5 (cg-RX-API-DMAC7.html) 2024-07-03

Family

ID=77127075

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2022580769A Pending JP2023532904A (ja) 2020-07-02 2021-07-01 修飾il-2ポリペプチドを含むポリペプチド及びその使用
JP2026032254A Pending JP2026094308A (ja) 2020-07-02 2026-03-02 修飾il-2ポリペプチドを含むポリペプチド及びその使用

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2026032254A Pending JP2026094308A (ja) 2020-07-02 2026-03-02 修飾il-2ポリペプチドを含むポリペプチド及びその使用

Country Status (12)

Country Link
US (1) US20230235005A1 (cg-RX-API-DMAC7.html)
EP (1) EP4175979A2 (cg-RX-API-DMAC7.html)
JP (2) JP2023532904A (cg-RX-API-DMAC7.html)
KR (1) KR20230035076A (cg-RX-API-DMAC7.html)
CN (1) CN116615440A (cg-RX-API-DMAC7.html)
AR (1) AR122863A1 (cg-RX-API-DMAC7.html)
AU (1) AU2021299552A1 (cg-RX-API-DMAC7.html)
CA (1) CA3184618A1 (cg-RX-API-DMAC7.html)
IL (1) IL299542A (cg-RX-API-DMAC7.html)
MX (1) MX2022016532A (cg-RX-API-DMAC7.html)
TW (1) TW202216745A (cg-RX-API-DMAC7.html)
WO (1) WO2022006380A2 (cg-RX-API-DMAC7.html)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20230112632A (ko) 2020-10-23 2023-07-27 애셔 바이오테라퓨틱스, 인크. 면역 세포 기능을 조절하기 위한 cd8 항원 결합 분자와의 융합
WO2022245500A1 (en) 2021-05-19 2022-11-24 Asher Biotherapeutics, Inc. Il-21 polypeptides and targeted constructs
TW202334193A (zh) * 2022-01-05 2023-09-01 美商英伊布里克斯公司 靶向γδ T細胞之經修飾IL-2多肽及其用途
EP4477673A4 (en) * 2022-02-11 2025-09-03 Jiangsu Hengrui Pharmaceuticals Co Ltd IMMUNOCONJUGATE AND ITS USE
CN119546343A (zh) * 2022-04-27 2025-02-28 亚设生物治疗公司 细胞因子融合蛋白与cd8抗原结合分子的组合
IL317511A (en) 2022-06-16 2025-02-01 Cephalon Llc IL-2 immunoconjugates attenuated by anti-PD-1 antibody and their uses
WO2024008126A1 (en) * 2022-07-06 2024-01-11 Elpiscience (Suzhou) Biopharma, Ltd. Il2 muteins and uses thereof
CN116041539B (zh) * 2022-10-31 2023-07-21 山东博安生物技术股份有限公司 Il-2突变体免疫缀合物
KR20250143339A (ko) * 2023-02-06 2025-10-01 메르크 파텐트 게엠베하 VHH-기반 NKp46 결합제
EP4770754A1 (en) 2023-08-30 2026-07-08 Xilio Development, Inc. Vhh masked cytokines and methods of use thereof

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2007528728A (ja) * 2004-03-05 2007-10-18 カイロン コーポレーション 改善されたインターロイキン−2ムテイン
JP2018512151A (ja) * 2016-05-04 2018-05-17 アムジエン・インコーポレーテツド 制御性t細胞の増殖のためのインターロイキン−2変異タンパク質
WO2020060122A1 (ko) * 2018-09-17 2020-03-26 (주)지아이이노베이션 Il-2 단백질 및 cd80 단백질을 포함하는 융합단백질 및 이의 용도
WO2020247843A2 (en) * 2019-06-05 2020-12-10 Asher Biotherapeutics, Inc. Fusions of mutant interleukin-2 polypeptides with antigen binding molecules for modulating immune cell function

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US6548640B1 (en) 1986-03-27 2003-04-15 Btg International Limited Altered antibodies
EP0590058B1 (en) 1991-06-14 2003-11-26 Genentech, Inc. HUMANIZED Heregulin ANTIBODy
WO1999029888A1 (en) 1997-12-05 1999-06-17 The Scripps Research Institute Humanization of murine antibody
US7217797B2 (en) 2002-10-15 2007-05-15 Pdl Biopharma, Inc. Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis
DK1678314T3 (da) 2003-10-22 2012-12-03 Keck Graduate Inst Fremgangsmåde til syntetisering af heteromultimere polypeptider i gær ved anvendelse af en haploid parringsstrategi
CN1961003B (zh) 2004-03-31 2013-03-27 健泰科生物技术公司 人源化抗TGF-β抗体
JP6592505B2 (ja) * 2014-04-24 2019-10-16 ザ ボード オブ トラスティーズ オブ ザ レランド スタンフォード ジュニア ユニバーシティー インターロイキン−2のスーパーアンタゴニスト、パーシャルアゴニスト及びアンタゴニスト
CN110325205B (zh) * 2016-12-22 2023-08-15 库尔生物制药有限公司 T细胞调节性多聚体多肽及其使用方法
AU2019288496B2 (en) * 2018-06-22 2024-11-21 Cugene Inc. Interleukin-2 variants and methods of uses thereof
CN113924311A (zh) * 2019-01-07 2022-01-11 印希比股份有限公司 包含修饰的il-2多肽的多肽及其用途

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2007528728A (ja) * 2004-03-05 2007-10-18 カイロン コーポレーション 改善されたインターロイキン−2ムテイン
JP2018512151A (ja) * 2016-05-04 2018-05-17 アムジエン・インコーポレーテツド 制御性t細胞の増殖のためのインターロイキン−2変異タンパク質
WO2020060122A1 (ko) * 2018-09-17 2020-03-26 (주)지아이이노베이션 Il-2 단백질 및 cd80 단백질을 포함하는 융합단백질 및 이의 용도
WO2020247843A2 (en) * 2019-06-05 2020-12-10 Asher Biotherapeutics, Inc. Fusions of mutant interleukin-2 polypeptides with antigen binding molecules for modulating immune cell function

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
STAUBER DJ. ET AL.: "Crystal structure of the IL-2 signaling complex: Paradigm for a heterotrimeric cytokine receptor", PROC NATL ACAD SCI USA, vol. 103, JPN6025044641, 2006, pages 2788 - 2793, ISSN: 0005722700 *
TAKEYOSHI M. ET AL.: "Cloning and sequence of guinea pig interleukin 2 (IL-2)", ARCH TOXICOL, vol. 72, JPN6025023818, 1998, pages 676 - 678, ISSN: 0005722699 *
ZURAWSKI SM. ET AL.: "Definition and spatial location of mouse interleukin-2 residues that interact with its heterotrimeri", EMBO J., vol. 12, no. 13, JPN6025023819, 1993, pages 5113 - 5119, ISSN: 0005722698 *

Also Published As

Publication number Publication date
KR20230035076A (ko) 2023-03-10
AR122863A1 (es) 2022-10-12
CN116615440A (zh) 2023-08-18
IL299542A (en) 2023-02-01
MX2022016532A (es) 2023-04-12
US20230235005A1 (en) 2023-07-27
CA3184618A1 (en) 2022-01-06
EP4175979A2 (en) 2023-05-10
WO2022006380A2 (en) 2022-01-06
JP2026094308A (ja) 2026-06-09
WO2022006380A3 (en) 2022-02-24
AU2021299552A1 (en) 2023-02-02
TW202216745A (zh) 2022-05-01

Similar Documents

Publication Publication Date Title
JP7594161B2 (ja) 修飾il-2ポリペプチドを含むポリペプチド及びその使用
JP7797614B2 (ja) Cd123結合性ポリペプチド及びその使用
JP7462611B2 (ja) Ox40結合性ポリペプチド及びその使用
US20230235005A1 (en) Polypeptides Comprising Modified IL-2 Polypeptides and Uses Thereof
JP2024164138A (ja) CLEC12a結合性ポリペプチド及びその使用
JP2024526835A (ja) Cd8結合ポリペプチド及びその使用
KR20220004750A (ko) Cd33 결합 폴리펩타이드 및 이의 용도
TW202319397A (zh) NKp46結合多肽及其用途
TW202328171A (zh) 靶向NKp46之經修飾之IL-2多肽及其用途
JP2025504363A (ja) γδT細胞結合ポリペプチド及びその使用
RU2849624C2 (ru) Полипептиды, содержащие модифицированный полипептид il-2, и их применения
US20250109203A1 (en) Gamma Delta T-Cell-Targeted Modified IL-2 Polypeptides and Uses Thereof

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240625

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20240625

A711 Notification of change in applicant

Free format text: JAPANESE INTERMEDIATE CODE: A711

Effective date: 20240925

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20250617

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250908

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20251104